Arch Biopartners has dosed the first patient in Canada in its Phase II clinical trial of LSALT peptide (Metablok) for acute ...

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

AbbVie’s stock price fell over 12% after emraclidine failed to meet its primary endpoints in the company’s Phase II ...

ViiV Healthcare has reported results from a trial of Dovato, a two-drug regimen consisting of dolutegravir/lamivudine ...

Cerevance has announced positive outcomes from its Phase I trial of CVN293, a drug candidate designed to treat ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

We explore the immense potential of gamma delta T cells, and the challenges in sourcing and scaling up sufficient volumes to ...

RAPT Therapeutics’ CEO Brian Wong said there was no “viable path forward” for the compound. Image credit: Shutterstock/Andrii Yalanskyi. RAPT Therapeutics has called it quits on a clinical programme ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Radella Pharmaceuticals has reported topline outcomes from a Phase Ia trial that assessed an investigational therapy for ...

Also known as a polymyxin B haemoperfusion (PMX), Toraymyxin is a haemoperfusion device that removes endotoxin, a toxic ...

The funding is set to support the initiation various trials of its assets. Credit: SOMKID THONGDEE/Shutterstock. Disc Medicine (Disc) has secured a $200m non-dilutive term loan facility from Hercules ...